Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for CVS Health (NYSE:CVS) from Market ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

CVS Health is seeing signs of stabilization in key business areas, prompting Leerink Partners to upgrade the stock from Market Perform to Outperform and raise its price target to $75 per share in a ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective boosted by analysts at Leerink Partners from $110 ...

Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...

NeuroPace, Inc. (Nasdaq: NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares ...

We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...